| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Placenta Accreta | 23 | 2026 | 182 | 13.000 |
Why?
|
| Hysterectomy | 16 | 2025 | 202 | 6.100 |
Why?
|
| Cesarean Section | 16 | 2026 | 426 | 5.210 |
Why?
|
| Pregnancy | 48 | 2026 | 7512 | 2.670 |
Why?
|
| Fetal Diseases | 6 | 2025 | 440 | 2.600 |
Why?
|
| Fetofetal Transfusion | 5 | 2025 | 206 | 1.840 |
Why?
|
| Fetoscopy | 6 | 2026 | 460 | 1.800 |
Why?
|
| Perinatal Death | 3 | 2023 | 29 | 1.730 |
Why?
|
| Meningomyelocele | 5 | 2026 | 260 | 1.580 |
Why?
|
| Retrospective Studies | 36 | 2026 | 17753 | 1.390 |
Why?
|
| Intensive Care Units | 2 | 2025 | 526 | 1.340 |
Why?
|
| Fetal Therapies | 3 | 2026 | 94 | 1.280 |
Why?
|
| Dacarbazine | 3 | 2015 | 94 | 1.280 |
Why?
|
| Postpartum Hemorrhage | 4 | 2025 | 111 | 1.260 |
Why?
|
| Pregnancy, Twin | 4 | 2025 | 191 | 1.220 |
Why?
|
| Case-Control Studies | 12 | 2026 | 3359 | 1.210 |
Why?
|
| Ultrasonography, Prenatal | 8 | 2026 | 986 | 1.170 |
Why?
|
| Placenta | 9 | 2025 | 504 | 1.130 |
Why?
|
| Apgar Score | 2 | 2025 | 48 | 1.110 |
Why?
|
| Female | 54 | 2026 | 70963 | 1.080 |
Why?
|
| Patient Admission | 2 | 2025 | 185 | 1.030 |
Why?
|
| Blood Loss, Surgical | 2 | 2025 | 168 | 1.010 |
Why?
|
| Oligohydramnios | 2 | 2025 | 46 | 1.000 |
Why?
|
| Uterine Hemorrhage | 2 | 2024 | 41 | 1.000 |
Why?
|
| Laser Coagulation | 2 | 2025 | 114 | 0.980 |
Why?
|
| Infant, Newborn | 17 | 2025 | 8635 | 0.960 |
Why?
|
| Antineoplastic Agents, Alkylating | 3 | 2015 | 97 | 0.940 |
Why?
|
| Watchful Waiting | 2 | 2025 | 73 | 0.870 |
Why?
|
| Balloon Occlusion | 1 | 2025 | 48 | 0.870 |
Why?
|
| Placenta Previa | 2 | 2022 | 66 | 0.860 |
Why?
|
| Conservative Treatment | 1 | 2025 | 46 | 0.850 |
Why?
|
| Blood Transfusion | 5 | 2025 | 294 | 0.840 |
Why?
|
| Blood Transfusion, Intrauterine | 1 | 2024 | 37 | 0.840 |
Why?
|
| Fetal Growth Retardation | 3 | 2025 | 253 | 0.840 |
Why?
|
| Humans | 61 | 2026 | 131163 | 0.810 |
Why?
|
| Pregnancy Outcome | 8 | 2026 | 623 | 0.810 |
Why?
|
| Amniotic Fluid | 3 | 2025 | 147 | 0.810 |
Why?
|
| Fetal Heart | 1 | 2025 | 132 | 0.800 |
Why?
|
| Uterine Artery Embolization | 1 | 2023 | 4 | 0.780 |
Why?
|
| Urinary Tract | 1 | 2023 | 55 | 0.770 |
Why?
|
| Tranexamic Acid | 1 | 2023 | 30 | 0.750 |
Why?
|
| Glioblastoma | 3 | 2015 | 371 | 0.730 |
Why?
|
| Oncologists | 1 | 2022 | 32 | 0.710 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2022 | 80 | 0.710 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2025 | 3763 | 0.670 |
Why?
|
| Clinical Trials as Topic | 1 | 2025 | 1129 | 0.660 |
Why?
|
| Adult | 24 | 2026 | 31282 | 0.660 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2015 | 821 | 0.640 |
Why?
|
| Prenatal Diagnosis | 7 | 2025 | 612 | 0.640 |
Why?
|
| Premature Birth | 3 | 2025 | 428 | 0.630 |
Why?
|
| Goiter | 2 | 2019 | 9 | 0.610 |
Why?
|
| Propylthiouracil | 2 | 2019 | 9 | 0.610 |
Why?
|
| Thyroxine | 2 | 2019 | 53 | 0.590 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2019 | 38 | 0.590 |
Why?
|
| Thyroid Diseases | 1 | 2019 | 27 | 0.570 |
Why?
|
| Spine | 1 | 2019 | 153 | 0.560 |
Why?
|
| Vulvovaginitis | 1 | 2017 | 2 | 0.510 |
Why?
|
| Neurosurgical Procedures | 1 | 2019 | 322 | 0.490 |
Why?
|
| Symptom Assessment | 1 | 2017 | 110 | 0.490 |
Why?
|
| Mental Disorders | 1 | 2024 | 910 | 0.480 |
Why?
|
| Twins, Monozygotic | 3 | 2025 | 124 | 0.470 |
Why?
|
| Prenatal Injuries | 1 | 2015 | 2 | 0.460 |
Why?
|
| Thyroid Hormones | 1 | 2015 | 54 | 0.440 |
Why?
|
| Bone Marrow Cells | 2 | 2015 | 243 | 0.440 |
Why?
|
| Hedgehog Proteins | 1 | 2015 | 199 | 0.400 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 420 | 0.370 |
Why?
|
| Polycythemia | 2 | 2024 | 46 | 0.370 |
Why?
|
| Spinal Dysraphism | 2 | 2026 | 261 | 0.360 |
Why?
|
| Insurance Coverage | 2 | 2023 | 120 | 0.360 |
Why?
|
| Anesthesia, General | 2 | 2022 | 140 | 0.330 |
Why?
|
| Treatment Outcome | 6 | 2025 | 12936 | 0.320 |
Why?
|
| Hernias, Diaphragmatic, Congenital | 2 | 2025 | 401 | 0.320 |
Why?
|
| Neurogenesis | 1 | 2012 | 206 | 0.320 |
Why?
|
| Predictive Value of Tests | 5 | 2026 | 2304 | 0.310 |
Why?
|
| Length of Stay | 2 | 2025 | 1421 | 0.290 |
Why?
|
| Brain Neoplasms | 2 | 2015 | 1306 | 0.290 |
Why?
|
| Gestational Age | 5 | 2026 | 1224 | 0.270 |
Why?
|
| MicroRNAs | 1 | 2015 | 889 | 0.270 |
Why?
|
| Hyperthyroidism | 2 | 2019 | 24 | 0.260 |
Why?
|
| Vasa Previa | 1 | 2026 | 9 | 0.250 |
Why?
|
| Chorion | 1 | 2025 | 16 | 0.230 |
Why?
|
| Vein of Galen Malformations | 1 | 2025 | 21 | 0.230 |
Why?
|
| Insurance, Health | 2 | 2023 | 146 | 0.220 |
Why?
|
| Pulmonary Edema | 1 | 2025 | 54 | 0.220 |
Why?
|
| Encephalocele | 1 | 2025 | 60 | 0.220 |
Why?
|
| Hydrops Fetalis | 1 | 2025 | 82 | 0.220 |
Why?
|
| Rhombencephalon | 1 | 2025 | 63 | 0.220 |
Why?
|
| Neurons | 2 | 2012 | 1979 | 0.220 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 57 | 0.220 |
Why?
|
| Polyhydramnios | 1 | 2025 | 52 | 0.210 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2026 | 171 | 0.210 |
Why?
|
| Rh Isoimmunization | 1 | 2024 | 27 | 0.210 |
Why?
|
| Parvoviridae Infections | 1 | 2024 | 31 | 0.210 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2025 | 162 | 0.210 |
Why?
|
| Spinal Cord | 1 | 2026 | 255 | 0.210 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2026 | 138 | 0.210 |
Why?
|
| Operative Time | 1 | 2025 | 201 | 0.210 |
Why?
|
| Transfection | 3 | 2015 | 962 | 0.210 |
Why?
|
| Sutures | 1 | 2024 | 63 | 0.200 |
Why?
|
| Pleural Effusion | 1 | 2024 | 103 | 0.200 |
Why?
|
| Risk Factors | 5 | 2026 | 11074 | 0.200 |
Why?
|
| Resuscitation | 1 | 2026 | 258 | 0.200 |
Why?
|
| Uterine Artery | 1 | 2023 | 27 | 0.190 |
Why?
|
| Cell Line, Tumor | 3 | 2015 | 3748 | 0.190 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2025 | 361 | 0.180 |
Why?
|
| Depression, Postpartum | 1 | 2023 | 52 | 0.180 |
Why?
|
| Phenotype | 1 | 2012 | 4497 | 0.180 |
Why?
|
| Cytomegalovirus Infections | 1 | 2024 | 223 | 0.180 |
Why?
|
| Neural Tube Defects | 1 | 2025 | 330 | 0.180 |
Why?
|
| Child Development | 1 | 2025 | 266 | 0.180 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2023 | 70 | 0.180 |
Why?
|
| Machine Learning | 1 | 2026 | 387 | 0.180 |
Why?
|
| Uterus | 1 | 2025 | 541 | 0.170 |
Why?
|
| Jaundice, Neonatal | 1 | 2021 | 10 | 0.170 |
Why?
|
| Artificial Intelligence | 1 | 2026 | 369 | 0.170 |
Why?
|
| Obstetrics | 1 | 2023 | 235 | 0.170 |
Why?
|
| Mental Health | 1 | 2024 | 378 | 0.160 |
Why?
|
| Rural Population | 1 | 2023 | 276 | 0.160 |
Why?
|
| Laser Therapy | 1 | 2023 | 243 | 0.160 |
Why?
|
| Medicaid | 1 | 2023 | 268 | 0.160 |
Why?
|
| Consensus | 1 | 2022 | 512 | 0.150 |
Why?
|
| Hypoglycemia | 1 | 2021 | 190 | 0.150 |
Why?
|
| Diabetes, Gestational | 1 | 2021 | 112 | 0.150 |
Why?
|
| United States | 4 | 2026 | 12072 | 0.150 |
Why?
|
| Registries | 1 | 2026 | 1634 | 0.150 |
Why?
|
| Echocardiography | 1 | 2025 | 1125 | 0.150 |
Why?
|
| Antithyroid Agents | 1 | 2019 | 4 | 0.150 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2024 | 514 | 0.150 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2011 | 83 | 0.150 |
Why?
|
| Neurodevelopmental Disorders | 1 | 2025 | 629 | 0.140 |
Why?
|
| Signal Transduction | 4 | 2015 | 4686 | 0.140 |
Why?
|
| Hypothyroidism | 1 | 2019 | 71 | 0.140 |
Why?
|
| Pregnancy Complications | 2 | 2023 | 567 | 0.130 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 2026 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 2904 | 0.130 |
Why?
|
| Candidiasis, Vulvovaginal | 1 | 2017 | 3 | 0.130 |
Why?
|
| Trichomonas Vaginitis | 1 | 2017 | 14 | 0.130 |
Why?
|
| Vaginosis, Bacterial | 1 | 2017 | 18 | 0.130 |
Why?
|
| Herpes Genitalis | 1 | 2017 | 10 | 0.130 |
Why?
|
| Lichen Planus | 1 | 2017 | 9 | 0.130 |
Why?
|
| Infant, Premature | 1 | 2022 | 872 | 0.130 |
Why?
|
| Lung | 1 | 2025 | 1535 | 0.130 |
Why?
|
| Hypertension | 1 | 2025 | 1356 | 0.120 |
Why?
|
| Pilot Projects | 1 | 2021 | 1445 | 0.120 |
Why?
|
| Neonatal Screening | 1 | 2019 | 207 | 0.120 |
Why?
|
| Health Services Accessibility | 1 | 2023 | 712 | 0.120 |
Why?
|
| Bone Marrow Neoplasms | 1 | 2015 | 22 | 0.120 |
Why?
|
| Blotting, Western | 2 | 2015 | 1013 | 0.110 |
Why?
|
| Fluoresceins | 1 | 2015 | 30 | 0.110 |
Why?
|
| Binding, Competitive | 1 | 2015 | 140 | 0.110 |
Why?
|
| Infant | 3 | 2026 | 13352 | 0.110 |
Why?
|
| Caspase 3 | 1 | 2015 | 121 | 0.110 |
Why?
|
| Patched Receptors | 1 | 2015 | 27 | 0.110 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2015 | 1205 | 0.110 |
Why?
|
| Animals | 7 | 2015 | 33912 | 0.110 |
Why?
|
| Cricetinae | 1 | 2015 | 362 | 0.110 |
Why?
|
| Patched-1 Receptor | 1 | 2015 | 38 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 267 | 0.110 |
Why?
|
| 3' Untranslated Regions | 1 | 2015 | 154 | 0.110 |
Why?
|
| Cells, Cultured | 4 | 2012 | 2885 | 0.100 |
Why?
|
| Hysterotomy | 2 | 2025 | 129 | 0.100 |
Why?
|
| Nerve Tissue Proteins | 2 | 2011 | 1075 | 0.100 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2015 | 194 | 0.100 |
Why?
|
| Transcriptional Activation | 1 | 2015 | 419 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2025 | 3147 | 0.100 |
Why?
|
| RNA Interference | 1 | 2015 | 491 | 0.100 |
Why?
|
| Neoplastic Stem Cells | 1 | 2015 | 330 | 0.100 |
Why?
|
| Gap Junctions | 1 | 2012 | 41 | 0.090 |
Why?
|
| Connexin 43 | 1 | 2012 | 34 | 0.090 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 36 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2014 | 286 | 0.090 |
Why?
|
| Up-Regulation | 1 | 2015 | 825 | 0.090 |
Why?
|
| Protein Kinase C | 1 | 2012 | 113 | 0.090 |
Why?
|
| Cats | 1 | 2012 | 117 | 0.090 |
Why?
|
| HEK293 Cells | 1 | 2015 | 801 | 0.090 |
Why?
|
| Antigens, Surface | 1 | 2012 | 112 | 0.090 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2012 | 101 | 0.090 |
Why?
|
| Mice, Inbred BALB C | 1 | 2014 | 978 | 0.090 |
Why?
|
| Breast Neoplasms | 2 | 2015 | 2602 | 0.090 |
Why?
|
| Adipogenesis | 1 | 2012 | 82 | 0.090 |
Why?
|
| Tachykinins | 1 | 2011 | 3 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 1618 | 0.090 |
Why?
|
| Species Specificity | 1 | 2012 | 470 | 0.090 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1882 | 0.090 |
Why?
|
| Osteogenesis | 1 | 2012 | 182 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2014 | 1011 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2015 | 713 | 0.080 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 680 | 0.080 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 1363 | 0.080 |
Why?
|
| Repressor Proteins | 2 | 2011 | 760 | 0.080 |
Why?
|
| Male | 5 | 2026 | 64957 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2015 | 2465 | 0.070 |
Why?
|
| Transplantation Tolerance | 1 | 2008 | 11 | 0.070 |
Why?
|
| Spinal Cord Injuries | 1 | 2011 | 273 | 0.070 |
Why?
|
| Cell Transdifferentiation | 1 | 2008 | 57 | 0.060 |
Why?
|
| Dopamine | 1 | 2008 | 246 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2008 | 151 | 0.060 |
Why?
|
| Observational Studies as Topic | 1 | 2026 | 106 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2011 | 2323 | 0.060 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2025 | 47 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2026 | 294 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2026 | 122 | 0.060 |
Why?
|
| Regeneration | 1 | 2008 | 230 | 0.060 |
Why?
|
| Lung Volume Measurements | 1 | 2025 | 72 | 0.050 |
Why?
|
| Edema | 1 | 2025 | 130 | 0.050 |
Why?
|
| Tensile Strength | 1 | 2024 | 47 | 0.050 |
Why?
|
| Polyesters | 1 | 2024 | 37 | 0.050 |
Why?
|
| Materials Testing | 1 | 2024 | 73 | 0.050 |
Why?
|
| Organ Size | 1 | 2025 | 407 | 0.050 |
Why?
|
| Cell Differentiation | 2 | 2008 | 1928 | 0.050 |
Why?
|
| Parity | 1 | 2023 | 77 | 0.050 |
Why?
|
| Cell Communication | 2 | 2015 | 188 | 0.050 |
Why?
|
| Hydrocephalus | 1 | 2025 | 245 | 0.050 |
Why?
|
| Fetal Death | 1 | 2023 | 115 | 0.050 |
Why?
|
| Syndrome | 1 | 2025 | 1155 | 0.050 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2023 | 80 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2023 | 263 | 0.040 |
Why?
|
| Constriction | 1 | 2021 | 46 | 0.040 |
Why?
|
| Logistic Models | 1 | 2026 | 1797 | 0.040 |
Why?
|
| Umbilical Cord | 1 | 2021 | 56 | 0.040 |
Why?
|
| Bilirubin | 1 | 2021 | 126 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2025 | 1267 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2023 | 1378 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2008 | 1939 | 0.040 |
Why?
|
| Young Adult | 3 | 2023 | 10103 | 0.040 |
Why?
|
| Co-Repressor Proteins | 2 | 2011 | 38 | 0.040 |
Why?
|
| Mice | 2 | 2014 | 18301 | 0.040 |
Why?
|
| Genetic Testing | 1 | 2024 | 1106 | 0.030 |
Why?
|
| Ohio | 1 | 2017 | 85 | 0.030 |
Why?
|
| Mass Screening | 1 | 2023 | 822 | 0.030 |
Why?
|
| Biomarkers | 1 | 2026 | 3385 | 0.030 |
Why?
|
| Anxiety | 1 | 2023 | 1014 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 6196 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5063 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 2012 | 2550 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2015 | 155 | 0.030 |
Why?
|
| Depression | 1 | 2023 | 1320 | 0.030 |
Why?
|
| Cell Survival | 1 | 2015 | 826 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2021 | 3829 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2023 | 6459 | 0.020 |
Why?
|
| Cellular Microenvironment | 1 | 2011 | 11 | 0.020 |
Why?
|
| Activating Transcription Factors | 1 | 2011 | 3 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2011 | 33 | 0.020 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2011 | 48 | 0.020 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2011 | 94 | 0.020 |
Why?
|
| Tretinoin | 1 | 2011 | 95 | 0.020 |
Why?
|
| Response Elements | 1 | 2011 | 102 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2011 | 110 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 255 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 526 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2011 | 341 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2011 | 226 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2026 | 15110 | 0.020 |
Why?
|
| Incidence | 1 | 2017 | 3360 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2012 | 1571 | 0.020 |
Why?
|
| Binding Sites | 1 | 2011 | 1133 | 0.020 |
Why?
|
| Nuclear Receptor Subfamily 4, Group A, Member 2 | 1 | 2008 | 33 | 0.020 |
Why?
|
| Zebrafish | 1 | 2011 | 418 | 0.020 |
Why?
|
| Biophysical Phenomena | 1 | 2008 | 39 | 0.020 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2008 | 21 | 0.020 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2008 | 46 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2008 | 62 | 0.020 |
Why?
|
| Sodium Channels | 1 | 2008 | 97 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2008 | 271 | 0.020 |
Why?
|
| Adult Stem Cells | 1 | 2008 | 50 | 0.020 |
Why?
|
| Wound Healing | 1 | 2011 | 490 | 0.020 |
Why?
|
| Protein Binding | 1 | 2011 | 1652 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2008 | 293 | 0.020 |
Why?
|
| Pluripotent Stem Cells | 1 | 2008 | 83 | 0.020 |
Why?
|
| Transduction, Genetic | 1 | 2008 | 276 | 0.020 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2008 | 288 | 0.020 |
Why?
|
| Immunization | 1 | 2008 | 269 | 0.020 |
Why?
|
| Adolescent | 2 | 2017 | 20987 | 0.020 |
Why?
|
| Models, Biological | 1 | 2011 | 1371 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2008 | 664 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 1826 | 0.010 |
Why?
|
| Homeodomain Proteins | 1 | 2008 | 555 | 0.010 |
Why?
|
| Child | 1 | 2023 | 26341 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2008 | 2406 | 0.010 |
Why?
|
| Middle Aged | 1 | 2017 | 28601 | 0.010 |
Why?
|
| Neoplasms | 1 | 2008 | 3016 | 0.010 |
Why?
|